NEW YORK, May 2, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") (NASDAQ: SNSS). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Sunesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, the Company's proposed treatment for relapsed/refractory AML. Sunesis advised investors that the decision followed recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use, during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product.
On this news, Sunesis's share price has fallen as much as $0.81, or 22.13%, during intraday trading on May 2, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sunesis-pharmaceuticals-inc--snss-300449941.html
SOURCE Pomerantz LLP